World News: 10:04 GMT Wednesday 15th May 2019. [Research and Markets via Globe Newswire via SPi World News]
Dublin, May 15, 2019 (GLOBE NEWSWIRE) -- The report has been added to offering. According to this research, the global wet age-related macular degeneration (AMD) market attained a size of $6.9 billion in 2018, and it is expected to reach $10.4 billion by 2024, advancing at a CAGR of 7.1% during the forecast period (2019-2024).The growth of the market is driven by the rising prevalence of AMD, lack of a specific treatment, and increasing aging population.Eylea, Lucentis, and Avastin are the drugs available worldwide for the treatment of wet AMD. Out of these, Eylea is anticipated to dominate the market in 2019-2024. The major factors escalating the demand for this drug in the global wet age-related macular degeneration market are the rising prevalence of AMD. On the basis of route of administration, the market is bifurcated into intravenously and intravitreally given drugs. During the forecast period, the drugs administered through the intravitreal route are predicted to witness the faster growth at a CAGR of 7.2% in the global wet age-related macular degeneration market. In 2018, North America held the largest revenue share, amounting to nearly $3.0 billion, in the global wet age-related macular degeneration market. This is ascribed to the increasing prevalence of wet AMD, rising number of drug approvals, and considerable presence of key players in the country.On a global ground, during the 2019-2024 period, the market is projected to observe the fastest growth with a CAGR of 8.8% in APAC, owing to the surge in the aging population, increase in the prevalence of AMD, and reimbursements offered by the government for treating wet age-related macular degradation in the region.Furthermore, APAC accounts for over one-third of the macular degeneration cases registered across the globe, which is anticipated to further rise during the forecast period. According to United Nations projections, nearly 24.0% of Asians will be of 60 years or above by 2050. Since aged people are more likely to develop AMD, the demand for medication for disease treatment is predicted to substantially rise in the region, resulting in the growth of the wet age-related macular degeneration market.Also, wet AMD treatment is quite expensive, as a result of which the government of countries such as South Korea and Malaysia have introduced some health insurance plans to cover the cost of the treatment to some extent and to lessen the burden of healthcare on people. For instance, under the universal government health insurance plan of South Korea's, during their lifetime, wet AMD patients can get up to 10 injections of ranibizumab. Thus, the increasing government initiatives are boosting the wet age-related macular degeneration market growth in the APAC region. 1.1 Research Objectives1.2 Market Definition1.3 Research Scope1.4 Key Stakeholders2.1 Secondary Research2.2 Primary Research2.3 Market Size Estimation2.4 Data Triangulation2.5 Assumptions for the Study4.1 Definition of Market Segments4.1.1 By Product126.96.36.199 Lucentis188.8.131.52 Eylea184.108.40.206 Avastin220.127.116.11 Others4.1.2 By Distribution Channel18.104.22.168 Direct22.214.171.124 Indirect4.1.3 By Age Group126.96.36.199 Above 80 years188.8.131.52 60-80 years184.108.40.206 40-59 years4.1.4 By Route of Administration220.127.116.11 Intravitreal18.104.22.168 Intravenous4.1.5 By End User22.214.171.124 Hospitals and clinics126.96.36.199 Research and academic institutes4.2 Market Dynamics4.2.1 Trends188.8.131.52 Positive clinical trial results and increasing approvals for pipeline drugs184.108.40.206 Growing number of acquisitions and collaborations4.2.2 Drivers220.127.116.11 Increasing prevalence of AMD18.104.22.168 Lack of availability of specific treatment22.214.171.124 Surge in geriatric population126.96.36.199 Impact analysis of drivers on market forecast4.2.3 Restraints188.8.131.52 Increasing usage of off-label drugs184.108.40.206 High cost of drugs and lack of insurance coverage220.127.116.11 Impact analysis of restraints on market forecast4.2.4 Opportunities18.104.22.168 Emerging market for wet AMD in APAC22.214.171.124 Prospective alternative therapies4.3 Porter's Five Forces Analysis4.4 Epidemiology Overview4.5 Pipeline Drugs for Wet AMD4.6 Pricing and Reimbursement Scenario4.6.1 Pricing4.6.2 Reimbursement5.1 By Product5.2 By Distribution Channel5.3 By Age Group5.4 By Route of Administration5.5 By End User5.6 By Region11.1 Clinical Trial Approvals and Results11.2 Acquisitions and Collaborations
For more information about this report visit
Research and Markets also offers services providing focused, comprehensive and tailored research.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Optical
Globe Newswire: 10:04 GMT Wednesday 15th May 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.